140 related articles for article (PubMed ID: 22322729)
1. Serum circulating immune complexes as prognostic indicators in premalignant and malignant lesions of oral cavity during and following radiotherapy.
Rai S; Mody RN
J Cancer Res Ther; 2012 Jan; 8 Suppl 1():S116-22. PubMed ID: 22322729
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of circulating immune complexes and serum immunoglobulins in oral cancer patients--a follow up study.
Parveen S; Taneja N; Bathi RJ; Deka AC
Indian J Dent Res; 2010; 21(1):10-5. PubMed ID: 20427899
[TBL] [Abstract][Full Text] [Related]
3. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
4. Role of bcl-2 oncoprotein in oral potentially malignant disorders and squamous cell carcinoma: an immunohistochemical study.
Sudha VM; Hemavathy S
Indian J Dent Res; 2011; 22(4):520-5. PubMed ID: 22124045
[TBL] [Abstract][Full Text] [Related]
5. Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions.
Porrini R; Vercellino V; Rocchetti V; Renò F; Giorda E; Pomato E; Cannas M; Sabbatini M
Minerva Stomatol; 2010 May; 59(5):233-9, 239-43. PubMed ID: 20502428
[TBL] [Abstract][Full Text] [Related]
6. Assessment of serum copper, iron and immune complexes in potentially malignant disorders and oral cancer.
Tiwari R; David CM; Mahesh DR; Sambargi U; Rashmi KJ; Benakanal P
Braz Oral Res; 2016 Oct; 30(1):e101. PubMed ID: 27737355
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of circulating immune complexes in malignant tumours of head and neck.
Das TK; Aziz M; Rattan A; Sherwani R
J Indian Med Assoc; 1995 Jan; 93(1):3-7. PubMed ID: 7759908
[TBL] [Abstract][Full Text] [Related]
8. Circulating immune complexes and trace elements (Copper, Iron and Selenium) as markers in oral precancer and cancer : a randomised, controlled clinical trial.
Khanna SS; Karjodkar FR
Head Face Med; 2006 Oct; 2():33. PubMed ID: 17040577
[TBL] [Abstract][Full Text] [Related]
9. Can quantifying free-circulating DNA be a diagnostic and prognostic marker in oral epithelial dysplasia and oral squamous cell carcinoma?
Shukla D; Kale AD; Hallikerimath S; Yerramalla V; Subbiah V
J Oral Maxillofac Surg; 2013 Feb; 71(2):414-8. PubMed ID: 22749518
[TBL] [Abstract][Full Text] [Related]
10. Detection of circulating immune complexes in patients with squamous cell carcinoma of the oral cavity.
Mukhopadhyaya R; Rao RS; Fakih AR; Gangal SG
J Clin Lab Immunol; 1986 Dec; 21(4):189-93. PubMed ID: 3494132
[TBL] [Abstract][Full Text] [Related]
11. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
12. Role of circulating immune complexes in prognostic evaluation and management of genitourinary cancer patients.
Aziz M; Das TK; Rattan A
Indian J Cancer; 1997 Sep; 34(3):111-20. PubMed ID: 9491672
[TBL] [Abstract][Full Text] [Related]
13. Immunology of premalignant and malignant conditions of the oral cavity. II. Circulating immune complexes.
Balaram P; Pillai MR; Abraham T
J Oral Pathol; 1987 Sep; 16(8):389-91. PubMed ID: 3121822
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer.
Rajpura KB; Patel PS; Chawda JG; Shah RM
J Oral Pathol Med; 2005 May; 34(5):263-7. PubMed ID: 15817068
[TBL] [Abstract][Full Text] [Related]
15. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of patients with premalignant and malignant lesions of the oral cavity.
Rajendran R; Remani P; Vijayakumar T; Vasudevan DM
Ann Dent; 1990; 49(1):36-8, 51. PubMed ID: 2346298
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of circulating immune complexes (CIC) in patients with malignant salivary gland tumors.
Lotfy M; Yassin S; Ezz M
Egypt Dent J; 1993 Oct; 39(4):547-8. PubMed ID: 9588121
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of serum levels of SCC antigen in cancers of the oral cavity].
Yoshida H; Kinehara M; Sato K
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3595-601. PubMed ID: 2817910
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility and monitoring of breast cancer by circulating immune complexes.
Dass TK; Aziz M; Rattan A; Tyagi SP
Indian J Pathol Microbiol; 1992 Oct; 35(4):298-307. PubMed ID: 1344219
[TBL] [Abstract][Full Text] [Related]
19. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital.
Hsue SS; Wang WC; Chen CH; Lin CC; Chen YK; Lin LM
J Oral Pathol Med; 2007 Jan; 36(1):25-9. PubMed ID: 17181738
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment outcome of oral premalignant lesions.
Holmstrup P; Vedtofte P; Reibel J; Stoltze K
Oral Oncol; 2006 May; 42(5):461-74. PubMed ID: 16316774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
